Edwards Lifesciences Corporation (EW) Stock Rating Reaffirmed by BMO Capital Markets

BMO Capital Markets reiterated their buy rating on shares of Edwards Lifesciences Corporation (NYSE:EW) in a research note published on Friday, September 1st. BMO Capital Markets currently has a $132.00 price target on the medical research company’s stock.

EW has been the subject of several other research reports. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a strong-buy rating to a buy rating in a report on Tuesday, June 13th. Canaccord Genuity reaffirmed a buy rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a hold rating to a buy rating and set a $129.00 price target for the company in a report on Thursday, June 1st. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Edwards Lifesciences Corporation in a report on Tuesday, May 16th. They issued a conviction-buy rating and a $138.00 price target for the company. Finally, Cowen and Company reissued an outperform rating and issued a $135.00 price target (up from $130.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $120.75.

Edwards Lifesciences Corporation (NYSE EW) opened at 113.50 on Friday. The stock has a market capitalization of $23.97 billion, a price-to-earnings ratio of 34.43 and a beta of 0.64. The company’s 50-day moving average is $113.99 and its 200 day moving average is $108.88. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.20. The company had revenue of $842.00 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.76 earnings per share. Equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://ledgergazette.com/2017/09/17/edwards-lifesciences-corporation-ew-receives-buy-rating-from-bmo-capital-markets.html.

In related news, VP Donald E. Bobo, Jr. sold 5,600 shares of the firm’s stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $117.15, for a total value of $656,040.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $114.80, for a total value of $3,776,920.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 163,541 shares of company stock valued at $18,712,719. 2.13% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. ETF Managers Group LLC bought a new position in Edwards Lifesciences Corporation during the second quarter worth about $112,000. YorkBridge Wealth Partners LLC bought a new position in Edwards Lifesciences Corporation during the first quarter worth about $110,000. NEXT Financial Group Inc raised its position in shares of Edwards Lifesciences Corporation by 91.7% during the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock worth $115,000 after purchasing an additional 500 shares during the period. Shine Investment Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences Corporation during the second quarter worth about $126,000. Finally, Cornerstone Advisors Inc. raised its position in shares of Edwards Lifesciences Corporation by 25.1% during the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after purchasing an additional 219 shares during the period. Hedge funds and other institutional investors own 82.36% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply